ACRV acrivon.com: Accounting Value per Share

Acrivon Therapeutics is led by recognized experts who ensure the operational transparency of the innovative APAM proteomic system. The actual book value per share reflects current asset dynamics, with the metric currently standing at 2.02. A lack of sales and a dependence on test results deprive the company of pricing power. Furthermore, global conflicts are hindering reagent logistics and the execution of international research.

Acrivon Therapeutics Inc (ACRV) - Accounting Value per Share from 04/28/2023 to 10/27/2026

Summary analytical data breakdowns for acrivon.com (ACRV)

- price and consensus price forecast:

Price Chart Acrivon|ACRV - Fair Value Consensus

- market capitalization data:

Market Valuation Acrivon Therapeutics, Inc.|ACRV - Total Company Value

- book capitalization data:

Net Assets per Single Share Acrivon Therapeutics|ACRV - Company Net Assets|Market Capitalization to Book Value Ratio acrivon.com|ACRV - Company Total Asset Base

- debt and liquidity data:

Debt to Equity Acrivon Therapeutics|ACRV - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Acrivon Therapeutics, Inc.|ACRV - Company Total Debt|Debts to Book Capitalization Acrivon Therapeutics, Inc.

Analysis of all company metrics:Acrivon, ACRV

To select assets with a high margin of safety, analyzing net assets divided by the number of issued shares is critical. This metric objectifies the cost of capital for Acrivon Therapeutics (ACRV) by weighing AI design and synthesis automation costs against actual clinical trial expenditures, allowing for an assessment of the fair book value per share.

Competitor analysis for Acrivon Therapeutics

Net Assets per Single Share NovoCure Corp (NVCR)|Alpha Tau Corp (DRTS) - Accounting Value of a Share|Fortress Biotech, Inc. (FBIO) - Accounting Value per Share|ALLR (Allarity Therapeutics, Inc.) - Net Assets per Single Share